# A Study of MHB036C for Advanced Solid Tumor

Source: https://onco.cc/trials/nct06373406/  
OnCo record `nct06373406` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MHB036C in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, active and no longer recruiting.

## Summary

A Study of MHB036C for Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT06373406 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants enrolled, started 2023-05-26 and due to reach its primary completion in 2025-12. Interventions recorded: MHB036C.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06373406
- Phase: 1/2
- Setting: A Phase I/II, Dose Escalation and Dose Expansion Study of MHB036C for Advanced Solid Tumor to Evaluate the Tolerability/Safety, Pharmacokinetics and Efficacy
- Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT06373406: https://clinicaltrials.gov/study/NCT06373406

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [MHB036C](https://onco.cc/drugs/mhb036c/)

---
JSON: https://onco.cc/api/v1/entities/nct06373406.json